Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-Synuclein oligomer formation: Relevance to Parkinson's disease

Current Pharmaceutical Design

Volumn 18, Issue 1, 2012, Pages 76-84

  Gadad, Bharathi Shrikanth ^a,c   Subramanya, Parvathy K ^a   Pullabhatla, Srinivas ^a   Shantharam, Indi S ^b   Rao, K S ^a,d  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d INSTITUTO DE INVESTIGACIONES CIENTÍFICAS Y SERVICIOS DE ALTA TECNOLOGÍA   (Panama)

Author keywords

Aggregation; Alpha synuclein; Curcumin glucoside; Oligomer; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CURCUMIN; CURCUMIN DIGLUCOSIDE; CURCUMIN DIGLUCOSIDE TETRA ACETATE; CURCUMIN GLUCOSIDE; CURCUMIN MONOGLUCOSIDE; CURCUMIN MONOGLUCOSIDE TETRA ACETATE; MONOMER; OLIGOMER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; DOSE RESPONSE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; FIBER; FLUORESCENCE; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MICROCALORIMETRY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; STOICHIOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ALPHA-SYNUCLEIN; CALORIMETRY; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLUCOSIDES; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SOLUBILITY;

EID: 84855849474     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212798919093     Document Type: Article

References (60)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
2. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998; 251: 205-8.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
4. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alphasynuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998; 55: 151-2.
5. Lucking CB, Brice A. Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 2000; 57: 1894-908.
6. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-15.
7. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32.
8. Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995; 34: 10139-45.
9. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-15.
10. Wright PE, Dyson HJ. Intrinsically unstructured proteins: reassessing the protein structure-function paradigm. J Mol Biol 1999; 293: 321-31.
11. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000; 41: 415-27.
12. Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 1998; 436: 309-12.
13. El-Agnaf OM, Jakes R, Curran MD, Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998; 440: 67-70.
14. Li HT, Lin XJ, Xie YY, Hu HY. The early events of alphasynuclein oligomerization revealed by photo-induced cross-linking. Protein Pept Lett 2006; 13: 385-90.
15. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11: 213-28.
16. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999; 274: 19509-12.
17. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571-6.
18. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001; 276: 10737-344.
19. Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-102.
20. Outeiro TF, Putcha P, Tetzlaff JE, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008; 3: e1867.
21. Volles MJ, Lansbury PT, Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003; 42: 7871-18.
22. Maguire-Zeiss KA, Wang CI, Yehling E, et al. Identification of human alpha-synuclein specific single chain antibodies. Biochem Biophys Res Commun 2006; 349: 1198-205.
23. Rao JN, Dua V, Ulmer TS. Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry 2008; 47: 4651-6.
24. Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007; 46: 1868-77.
25. Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008; 15: 558-66.
26. Luk KC, Hyde EG, Trojanowski JQ, Lee VM. Sensitive fluorescence polarization technique for rapid screening of alphasynuclein oligomerization/fibrillization inhibitors. Biochemistry 2007; 46: 12522-9.
27. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-6.
28. Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002; 61: 191-202.
29. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid by congo red spectral shift assay. Methods Enzymol 1999; 309: 285-305.
30. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid betapeptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem 1999; 266: 66-76.
31. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004; 75: 742-50.
32. Ono K, Yamada M. Antioxidant compounds have potent antifibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97: 105-15.
33. Liu Z, Yu Y, Li X, Ross CA, Smith WW. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol Res 2011; 63: 439-44.
34. Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci 2010; 11: 57.
35. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-901.
36. Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta 2005; 1751: 119-39.
37. Kelly SM, Price NC. Circular dichroism to study protein interactions. Curr Protoc Protein Sci 2006; Chapter 20: Unit 2010.
38. Dubochet J, Ducommun M, Zollinger M, Kellenberger E. A new preparation method for dark-field electron microscopy of biomacromolecules. J Ultrastruct Res 1971; 35: 147-67.
39. Garcia-Fuentes L, Baron C, Mayorga OL. Influence of dynamic power compensation in an isothermal titration microcalorimeter. Anal Chem 1998; 70: 4615-23.
40. Ferreon AC, Deniz AA. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation. Biochemistry 2007; 46: 4499-509.
41. LeVine H, 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993; 2: 404-10.
42. Trojanowski JQ, Lee VM. Parkinson's disease and related alphasynucleinopathies are brain amyloidoses. Ann N Y Acad Sci 2003; 991: 107-10.
43. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2: 492-501.
44. Kostka M, Hogen T, Danzer KM, et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem 2008; 283: 10992-1003.
45. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alphasynuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging 2010; 31: 953-68.
46. Madine J, Doig AJ, Middleton DA. Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solidstate NMR. J Am Chem Soc 2008; 130: 7873-81.
47. Goldberg MS, Lansbury PT, Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000; 2: E115-9.
48. Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1998; 37: 17882-9.
49. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Antiamyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001; 487: 404-7.
50. Pollack SJ, Sadler, II, Hawtin SR, Tailor VJ, Shearman MS. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci Lett 1995; 197: 211-4.
51. Ubhi K, Rockenstein E, Mante M, et al. Rifampicin reduces alphasynuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008; 19: 1271-6.
52. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 2004; 279: 26846-57.
53. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-81.
54. Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 2005; 336: 444-9.
55. Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989; 14: 175-85.
56. Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids. Arzneimittelforschung 1996; 46: 169-71.
57. Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 1997; 11: 49-62.
58. Petkova AT, Ishii Y, Balbach JJ, et al. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002; 99: 16742-7.
59. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 2003; 81: 678-99.
60. Nuscher B, Kamp F, Mehnert T, et al. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. J Biol Chem 2004; 279: 21966-75.